Management of Rheumatic Heart Disease with Atrial Fibrillation

Immediate Hemodynamic Assessment and Stabilization

For a patient with rheumatic heart disease presenting with AF in RVR at heart rate 200 bpm, immediate assessment of hemodynamic stability is critical, and if the patient shows severe hemodynamic compromise, ongoing ischemia, or signs of decompensation, urgent direct-current cardioversion is required 1
If the patient is hemodynamically stable, proceed with pharmacological rate control as the initial strategy, according to the American College of Cardiology 2, 1

Intravenous diltiazem or metoprolol should be administered as first-line therapy, targeting a heart rate <110 bpm at rest, as recommended by the American College of Cardiology 1
In the absence of pre-excitation, IV beta-blocker administration (or nondihydropyridine calcium channel antagonist) is recommended to slow ventricular response acutely, with caution in patients with overt congestion or hypotension, according to the American College of Cardiology 2

Patients with rheumatic heart disease typically have valvular involvement (most commonly mitral stenosis), which classifies this as valvular AF requiring warfarin anticoagulation rather than direct oral anticoagulants, as stated by the American Heart Association 3
Calculate CHA₂DS₂-VASc score immediately, though rheumatic heart disease with AF generally mandates anticoagulation regardless of score, according to the American College of Cardiology 3

If monotherapy with a beta-blocker or calcium channel blocker fails to achieve adequate rate control, combination therapy with digoxin plus a beta-blocker (or nondihydropyridine calcium channel antagonist) is reasonable, as recommended by the American College of Cardiology 2, 1
Digoxin is effective for controlling resting heart rate but not exercise heart rate in patients with HF with reduced EF, according to the American College of Cardiology 2

Once acute rate control is achieved, transition immediately to oral diltiazem 120-360 mg daily (extended release) or oral metoprolol tartrate 25-200 mg twice daily for sustained rate control, as recommended by the American College of Cardiology 3

For patients with AF and rapid ventricular response causing or suspected of causing tachycardia-induced cardiomyopathy, it is reasonable to achieve rate control by either AV nodal blockade or a rhythm-control strategy, according to the American College of Cardiology 2
If tachycardia-induced cardiomyopathy is confirmed or suspected, AV node ablation with ventricular pacing is reasonable when pharmacological therapy is insufficient or not tolerated, as stated by the American College of Cardiology 2, 3

For patients with chronic HF who remain symptomatic from AF despite a rate-control strategy, it is reasonable to use a rhythm-control strategy, according to the American College of Cardiology 2
Younger patients, those with recent-onset AF, or highly symptomatic patients may benefit more from rhythm control, as recommended by the American Heart Association 3

Arrange close outpatient follow-up within 1-2 weeks to assess response to therapy, and ensure appropriate monitoring for anticoagulation (INR for warfarin), as stated by the American College of Cardiology 3
Assessment of heart rate control during exercise and adjustment of pharmacological treatment to keep the rate in the physiological range is useful in symptomatic patients during activity, according to the American College of Cardiology 2

Never use AV nodal blocking agents (beta-blockers, calcium channel blockers, digoxin) if pre-excitation (WPW) is present, as they can accelerate conduction through the accessory pathway and precipitate ventricular fibrillation, as warned by the American College of Cardiology 1
Avoid IV calcium channel blockers or beta-blockers if decompensated heart failure is present, as this may cause harm, according to the American College of Cardiology 3, 1